Sedana Medical Q2 adjusted EBITDA loss narrows to SEK 1.9 million; net sales slip 1% to SEK 49.1 million y/y

• Sedana Medical posted Q2 net sales of SEK 49.1 million, down 1% year on year.
• EBITDA loss narrowed to SEK 1.9 million from SEK 4.1 million, lifting the EBITDA margin to -4% from -8%.
• Gross margin rose to 73% from 70%, supported by lower cost of goods for Sedaconda ACD following the Malaysia supplier acquisition.
• Germany net sales fell 23% on lower ICU occupancy, while other direct markets climbed 41% and distributor markets increased 23%.
• US NDA was submitted in June 2026; FDA review is underway with a PDUFA date expected in August/September.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sedana Medical AB published the original content used to generate this news brief on July 17, 2026, and is solely responsible for the information contained therein.